|Day Low/High||69.67 / 70.80|
|52 Wk Low/High||56.56 / 73.34|
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
These companies were counted out way too early in the post-pandemic environment and the sellers are experiencing some real regret.
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
The upgrade got my attention, but positive-looking charts pushed me over the edge.
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
Plus, a quick look at Southwest Airlines and why it remains the one airline to own.
The stock is simply too cheap, given its strong results to begin 2020, and a highly profitable business model that generates huge amounts of cash flow.
What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.
Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.
The short-term story for financial markets has been all about fiscal policy. This remains true.
I don't care for Washington but I have no choice. If I only stick to stocks, I would have buried you.
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
As is so often the case, the bears are unable to close the deal when it looks like they have an edge.
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.
The Fed's money pumping has elevated new tech, but Jay Powell and the government haven't done any favors for many other stocks.
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.